Not approved and not available to prescribe. Figures come from different trials, phases and lengths — they are not a ranking.
Where each drug is
Filed with the FDA (1 drug)
In Phase 3 trials (4 drugs)
Daily pill · Switches on the GLP-1 receptor
Timeline: Not yet known — AstraZeneca has not given a date (Phase 3 began mid-2026)
Details →Monthly injection · Blocks GIP, activates GLP-1 receptors
Timeline: 2027+ (estimated — not confirmed)
Details →Weekly injection · Acts on GIP, GLP-1 and glucagon
Timeline: 2027 (estimated — not confirmed)
Details →Weekly injection · Acts on glucagon and GLP-1 receptors
Timeline: Not yet known — Boehringer Ingelheim has not given a date
Details →Common questions
Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice
About the trial data on this page
Each figure below is read directly from the drug's own data and is tied to the specific trial and dose that produced it — figures come from different trial phases, doses and lengths and are not directly comparable to each other. Most are from Phase 2 trials or early Phase 3 results; Phase 2 results frequently overestimate final Phase 3 outcomes.
- Retatrutide: 28.7% (TRIUMPH-4 (Phase 3) · 12 mg, 68 weeks, adults with knee osteoarthritis)
- CagriSema: 22.7% (REDEFINE 1 (Phase 3) · 68 weeks, people who kept taking it (20.4% overall))
- Amycretin: 22% (Phase 1b/2a (subcutaneous) · 20 mg weekly, 36 weeks)
- MariTide: 20% (Phase 2 dose-finding study · Highest dose, 52 weeks)
- Elecoglipron: 11.8% (VISTA (Phase 2b) · 75 mg dose, 36 weeks)
- Survodutide: 16.6% (SYNCHRONIZE-1 (Phase 3) · 6.0 mg, 76 weeks, kept taking it (13.0% overall))
Next step most people take
Built with agentic AI tools and not a substitute for medical advice
Last reviewed: